Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis. The FDA’s Psychopharmacologic Drugs Advisory Committee will review Acadia’s Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer’s disease, according to the Alzheimer’s Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500 has fallen 23%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.